<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04429022</url>
  </required_header>
  <id_info>
    <org_study_id>STUDY00004549</org_study_id>
    <nct_id>NCT04429022</nct_id>
  </id_info>
  <brief_title>Multimodal Pain Management After Robotic-Assisted Total Laparoscopic Hysterectomy</brief_title>
  <acronym>RA-TLH</acronym>
  <official_title>Multimodal Pain Management After Robotic-Assisted Total Laparoscopic Hysterectomy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>State University of New York at Buffalo</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>State University of New York at Buffalo</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Hysterectomy is the most common major gynecologic surgery performed in the US and is
      performed for a variety of indications including malignancy, pelvic mass, endometriosis,
      leiomyoma, and pelvic organ prolapse. The traditional regimen for pain control
      post-operatively is opioid-based however in light of the opioid epidemic, a transition to
      non-opioid pain medication regimens is desired by both physicians and patients alike. The
      goal of this study is to develop a multimodal non-opioid pain medication regimen that
      minimizes postoperative opioid use after robotic assisted total laparoscopic hysterectomy.
      Historical controls from Jan 1, 2017 to Jan 1, 2020 will be compared to our treatment arm
      from July 1, 2020 to July 1, 2022. Included in our treatment protocol is paracervical block
      and local ropivacaine at abdominal incision sites at surgical start, gabapentin and
      acetaminophen preoperatively and postoperatively, and celecoxib postoperatively. Opioid use
      will be measured 0-3 h postop and 3-24h postop (as surrogate marker of time spent recovering
      in the Post Anesthesia Care Unit (PACU), and during the full length of hospital stay); pain
      scores will additionally be measured.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Material and Methods:

      This is a prospective cohort study with historical controls between January 2017 and July
      2022. Cases of those receiving a non-opioid multimodal pain regimen will be compared to
      historical controls of those receiving a traditional opioid pain regimen. All patients
      undergoing robotic total laparoscopic hysterectomy, with or without bilateral
      salpingo-oophorectomy, with a uterine weight ≤325 grams will be included in this study.
      Multimodal pain regimen will include the following:

      Protocol:

      Pre-Op: - Gabapentin 600mg PO PO x 1 prior to surgery (in pre-op area)

        -  Acetaminophen 1000mg PO x1 prior to surgery (in pre-op area)

      Intra-Op:

        -  Paracervical block with local anesthetic (0.5% ropivacaine); 10 mL bilaterally (2 point)
           for total of 20mL

        -  Local anesthetic (0.5% ropivacaine) at all laparoscopic port sites; another 10mL

        -  Will operate at &lt;15mmHg intra-abdominal pressure with goal of &lt;12mmHg

        -  At end of procedure during closure of fascia, give 30mg ketorolac IV x 1

      Post-Op:

        -  Gabapentin 300mg PO BID for 7 days

        -  Acetaminophen 1000mg PO q6h x 2 days then 1000mg q6h PRN

        -  Celecoxib 200mg PO q 12h x 7d

        -  Dilaudid 1mg IV PRN q3h while inpatient; oxycodone 12 tabs x 5mg upon discharge (90MME)

        -  if patient did not use any opioids postoperatively while inpatient, will not prescribe
           opioid medication upon discharge

        -  Also include standard post-op medications such as zofran, reglan, mylicon…

      Our primary outcomes are opioid pain medication needed after surgery and pain scores as rated
      subjectively by the patient. Our secondary outcomes include length of stay in hours and
      whether the patient returns to the clinic or emergency department due to post operative pain
      within a 2 week period.
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">July 1, 2020</start_date>
  <completion_date type="Anticipated">January 1, 2023</completion_date>
  <primary_completion_date type="Anticipated">July 1, 2022</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <intervention_model_description>Prospective cohort with retrospective controls</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Total opioid pain medications required 0-3h post op in morphine milligram equivalents (MME)</measure>
    <time_frame>0-3 hours after surgery</time_frame>
    <description>Total opioid pain medications required 0-3h post op in morphine milligram equivalents (MME)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Total opioid pain medications required through 3-24h post op in MME</measure>
    <time_frame>3-24 hours after surgery</time_frame>
    <description>Total opioid pain medications required through 3-24h post op in MME</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Pain scores</measure>
    <time_frame>0-24 hours after surgery</time_frame>
    <description>Subjective, Score 1-10 with 1 being no pain and 10 being severe pain</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Length of stay in hours</measure>
    <time_frame>0- 72 hours</time_frame>
    <description>Length of stay in hours</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of patients with return to the clinic, emergency department due to post operative pain within a 2 week period</measure>
    <time_frame>0-14 days</time_frame>
    <description>Number of patients with return to the clinic, emergency department due to post operative pain within a 2 week period</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">200</enrollment>
  <condition>Pain, Postoperative</condition>
  <arm_group>
    <arm_group_label>Prospective cohort</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Pre-Op:
Gabapentin 600mg PO PO x 1 prior to surgery (in pre-op)
Acetaminophen 1000mg PO x1 prior to surgery (in pre-op)
Intra-Op:
Paracervical block with local anesthetic (0.5% ropivacaine); 10 mL bilaterally (2 point) for total of 20mL
Local anesthetic (0.5% ropivacaine) at all laparoscopic port sites; another 10mL
Will operate at &lt;15mmHg intra-abdominal pressure, with goal of &lt;12mmHg
At end of procedure during closure of fascia, give 30mg ketorolac IV x 1
Post-Op:
Gabapentin 300mg PO BID for 7 days
Acetaminophen 1000mg PO q6h x 2 days then 1000mg q6h PRN
Celecoxib 200mg PO q 12h x 7d
Dilaudid 1mg IV PRN q3h while inpatient; oxycodone 12 x 5mg upon discharge (90MME) if patient did not use any opioids postoperatively while inpatient, will not prescribe opioid medication upon discharge</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Historical Control</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Traditional post-operative opioid medication regimen: Dilaudid 1mg IV PRN q3h while inpatient; Perocets 12 x 5mg/325 (90MME) upon discharge</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Gabapentin</intervention_name>
    <description>600mg PO PO x 1 prior to surgery (in pre-op) 300mg PO BID for 7 days post op</description>
    <arm_group_label>Prospective cohort</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Acetaminophen</intervention_name>
    <description>Acetaminophen 1000mg PO x1 prior to surgery (in pre-op) Acetaminophen 1000mg PO q6h x 2 days then 1000mg q6h PRN post op</description>
    <arm_group_label>Prospective cohort</arm_group_label>
    <other_name>Tylenol</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Celecoxib</intervention_name>
    <description>Celecoxib 200mg PO q 12h x 7d post op</description>
    <arm_group_label>Prospective cohort</arm_group_label>
    <other_name>Celebrex</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ketorolac</intervention_name>
    <description>30mg IV once at end of hysterectomy procedure</description>
    <arm_group_label>Prospective cohort</arm_group_label>
    <other_name>Toradol</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Paracervical block with ropivacaine</intervention_name>
    <description>0.5% ropivacaine; 10 mL bilaterally (2 point) for total of 20mL</description>
    <arm_group_label>Prospective cohort</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Local anesthetic injection with ropivacaine at abdominal laparoscopic port sites</intervention_name>
    <description>0.5% ropivacaine; at all laparoscopic port sites; another 10mL ropivacaine in total</description>
    <arm_group_label>Prospective cohort</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Hydromorphone</intervention_name>
    <description>1mg IV PRN q3h, post op, while inpatient</description>
    <arm_group_label>Historical Control</arm_group_label>
    <arm_group_label>Prospective cohort</arm_group_label>
    <other_name>Dilaudid</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Oxycodone</intervention_name>
    <description>To be discharged home with: 12 tabs of 5mg PRN q4h</description>
    <arm_group_label>Prospective cohort</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Women undergoing robotic-assisted total laparoscopic hysterectomy, with or without
             bilateral salpingo-oophorectomy

          -  Uterine weight ≤325 grams

        Exclusion Criteria:

          -  contraindication to any study medications (h/o gastric bypass, gastric ulcers, CKD)

          -  current opioid prescription
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>25 Years</minimum_age>
    <maximum_age>90 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Sarah Andres, D.O.</last_name>
    <role>Principal Investigator</role>
    <affiliation>University at Buffalo</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Sarah E Andres, D.O.</last_name>
    <phone>7744515695</phone>
    <email>seandres@buffalo.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>George Danakas, M.D.</last_name>
    <phone>7166090861</phone>
    <email>gdanaka@buffalo.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Millard Fillmore Suburban Hospital</name>
      <address>
        <city>Williamsville</city>
        <state>New York</state>
        <zip>14221</zip>
        <country>United States</country>
      </address>
    </facility>
    <contact>
      <last_name>Sarah Andres, D.O.</last_name>
      <phone>774-451-5695</phone>
      <email>seandres@buffalo.edu</email>
    </contact>
    <contact_backup>
      <last_name>George Danakas, M.D.</last_name>
      <phone>7166090861</phone>
      <email>gdanaka@buffalo.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Sarah Andres, D.O.</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>George Danakas, M.D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Adajar, A. (2018). 73: Eliminating post-operative narcotic use after mini-laparoscopic hysterectomy: Effectiveness of a multimodal pain management regimen adopted into clinical practice. American Journal of Obstetrics and Gynecology, 218(2), S937-S938. https://doi.org/10.1016/j.ajog.2017.12.092</citation>
  </reference>
  <reference>
    <citation>Blanton E, Lamvu G, Patanwala I, Barron KI, Witzeman K, Tu FF, As-Sanie S. Non-opioid pain management in benign minimally invasive hysterectomy: A systematic review. Am J Obstet Gynecol. 2017 Jun;216(6):557-567. doi: 10.1016/j.ajog.2016.12.175. Epub 2016 Dec 30. Review.</citation>
    <PMID>28043841</PMID>
  </reference>
  <reference>
    <citation>Chopra, V., Kown, D., &amp; Sangha, R. (2018). Decreasing Postoperative Narcotic Use for Patients Undergoing Hysterectomy. Journal of Minimally Invasive Gynecology, 25(7), S194-S194. https://doi.org/10.1016/j.jmig.2018.09.526</citation>
  </reference>
  <reference>
    <citation>Mark J, Argentieri DM, Gutierrez CA, Morrell K, Eng K, Hutson AD, Mayor P, Szender JB, Starbuck K, Lynam S, Blum B, Akers S, Lele S, Paragh G, Odunsi K, de Leon-Casasola O, Frederick PJ, Zsiros E. Ultrarestrictive Opioid Prescription Protocol for Pain Management After Gynecologic and Abdominal Surgery. JAMA Netw Open. 2018 Dec 7;1(8):e185452. doi: 10.1001/jamanetworkopen.2018.5452.</citation>
    <PMID>30646274</PMID>
  </reference>
  <verification_date>June 2020</verification_date>
  <study_first_submitted>April 28, 2020</study_first_submitted>
  <study_first_submitted_qc>June 10, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">June 11, 2020</study_first_posted>
  <last_update_submitted>June 10, 2020</last_update_submitted>
  <last_update_submitted_qc>June 10, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">June 11, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>State University of New York at Buffalo</investigator_affiliation>
    <investigator_full_name>Sarah Andres</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>Hysterectomy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pain, Postoperative</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Acetaminophen</mesh_term>
    <mesh_term>Celecoxib</mesh_term>
    <mesh_term>Ketorolac</mesh_term>
    <mesh_term>Oxycodone</mesh_term>
    <mesh_term>Gabapentin</mesh_term>
    <mesh_term>Hydromorphone</mesh_term>
    <mesh_term>Ropivacaine</mesh_term>
    <mesh_term>Anesthetics, Local</mesh_term>
    <mesh_term>Anesthetics</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>IPD will not be available to other researchers</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

